84 related articles for article (PubMed ID: 21882947)
1. Cyclin-dependent kinases: bridging their structure and function through computations.
De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
[TBL] [Abstract][Full Text] [Related]
2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
3. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
6. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
Fisher RP
Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
[TBL] [Abstract][Full Text] [Related]
7. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
8. Small molecules as inhibitors of cyclin-dependent kinases.
Huwe A; Mazitschek R; Giannis A
Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
[TBL] [Abstract][Full Text] [Related]
9. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
10. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
11. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
12. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
13. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
14. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
Soos TJ; Meijer L; Nelson PJ
Drug News Perspect; 2006; 19(6):325-8. PubMed ID: 16971968
[TBL] [Abstract][Full Text] [Related]
15. [Cyclin-dependent kinase inhibitors in mammal cells].
Jiang H; Wang YC
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
[TBL] [Abstract][Full Text] [Related]
16. The role of the putative catalytic base in the phosphoryl transfer reaction in a protein kinase: first-principles calculations.
Valiev M; Kawai R; Adams JA; Weare JH
J Am Chem Soc; 2003 Aug; 125(33):9926-7. PubMed ID: 12914447
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
Pavletich NP
J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle.
Levin NMB; Pintro VO; de Avila MB; de Mattos BB; De Azevedo WF
Curr Drug Targets; 2017; 18(9):1104-1111. PubMed ID: 27848884
[TBL] [Abstract][Full Text] [Related]
19. Control of the G1/S transition.
Reed SI
Cancer Surv; 1997; 29():7-23. PubMed ID: 9338094
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
